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problems, particular socio-economic conditions, birth
rate, and levels of literacy, nutrition and mortality. This
means that any essential drug list must vary from one
country to another - with an appropriate list, perhaps
80 - 90% of diseases can be controlled reasonably effec-
tively but there must be room for the introduction of
the most modem and advanced preparations if the need
exists.
The industry, however, needs collaboration at a
national level and, as the spokesman remarked, it is
regrettable that a health ministry is often given a low
priority in developing countries, thereby preventing the
recruitment of the few available competent administra-
tors. Health budgets in many developing countries are
much lower than, for example, military budgets.
In the conclusions of the workshop, the point was
again made that, although the drug industry has not
been blameless nor have governments, the doctors must
accept the main responsibility for any unbalanced drug
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usage on the following grounds: doctors have controlled
the use of modem drugs from the time of their appear-
ance and have advised on the control of the drug trade
and the use of modem drugs by less educated health
staff and the population; doctors have trained and
supervised all categories of health staff who use the
drugs; and fmally, doctors in poor countries have tended
to follow the pattern of drug usage in rich countries, an
attitude which has permeated through to the lower
echelons of health staff.
In concluding, Erik HoIst called for more discussions
between members of various health professions on the
one hand and the pharmaceutical industry on the other.
'Even failure should be debated if we are to deal seriously
with the promotion of health in other countries.'
1. Man and drugs in the Third World - the doctor's viewpoint. Dan Med Bull
1984; 31: 1-38.
Medisyne in die Praktyk/Drugs in Practice
Paracetamol-induced acute renal failure in the absence of
severe liver damage
Acute renal failure following paracetamol overdosage in asso-
ciation with fulminant hepatic failure or massive hepatic necrosis
has been well described. 1- J This complication has been reponed
in about 10% of severely poisoned patients.3 Less commonly,
renal failure may occur in the absence of hepatic failure but in
association with abnormal liver function test results.4•5 Im-
pairment of renal function has been recorded in rare instances
in the absence of any clinical or biochemical evidence of liver
damage.6 Characteristically, liver damage is apparent 2 - 4
days after ingestion of paracetamol whereas renal failure be-
comes evident 1 week after ingestion. However, back pain,
proteinuria and haematuria occur within 36 - 48 hours and are
reponed invariably to herald renal failure. 6 It may be mild and
transient, or severe enough to necessitate dialysis. In moderately
severe cases not requiring dialysis, serum urea and creatinine
concentrations increase progressively for 7 - 10 days before
gradual recovery of renal function. i
Paracetamol overdosage is thought to cause renal tubular
necrosis in the same way that it damages the liver, through
covalent binding of a highly reactive metabolite normally
trapped by conjugation with reduced glutathione.s HypoteI?-sion
or volume depletion can contribute to the renal damage.
Sulphydryl compounds such as N-acetylcysteine may prevent
renal as well as hepatic damage if given within· about 10 hours
of paracetamol overdosage. J .
We have recently treated a l6-year-old girl who ingested
8 - 10 g paracetamol (16 - 20 Beserol tablets: paracetamol 500
mg, chlormezanone 100 mg per tablet). Although she was seen
by her doctor, blood levels of paracetamol were not measured
and no specific treatment was given. During the following 2
days she vomited on a number of occasions and complained of
severe loin pain. Decreased urine output was noted on the 3rd
day after drug ingestion. She was admitted to hospital on the
4th day, when the only clinical abnormalities were a tempera-
ture of 37,4°C, mildly decreased hydration with a blood
pressure of 105170 mmHg, and marked bilateral loin tender-
ness. There was no hepatomegaly or liver tenderness. The
urine contained 1+ blood and polygonal tubular cells on
microscopy. The urine urea level was 119 mmoVl and the
sodium level 37 mmoVl. Urine culture was negative. The
serum urea level was 13,3 mmoVl (normal 1,7 - 6,7 mmoVl)
and the creatinine level was 374 j.LmoVl (normal 75 - 115
j.LmoVl). Liver function tests revealed only mild abnormality
with a total bilirubin value of 19 j.LmoVl (normal 1 - 17
j.LmoVl), aspanate transaminase 32 lUll (normal 0 - 12 lUll)
and l'-glutamyl transferase 63 lUll (normal 6 - 28 lUll).
Ultrasonography of the abdomen revealed enlarged kidneys
with no evidence of hydronephrosis. With attention to adequate
hydration, renal function returned to normal 9 days after
ingestion of the paracetamol.
Chlormezanone is not known to be nephrotoxic but it is an
enzyme inducer and might have contributed to the increased
formation of toxic paracetamol metabolites. Although dehydra-
tion may have contributed to the renal impairment the features
were compatible with a toxic, paracetamol-induced, acute
tubular necrosis. The low urinary urea and the high urinary
sodium levels favour acute tubular damage rather than pre-
renal failure. The swollen kidneys are also consistent with
oedema secondary to renal damage. Renal capsular swelling
was thought to account for the loin pain.
Although the renal failure was mild and did not require
dialysis, it might have been prevented by early administration
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of N-acetylcysteine. This case also highlights the occurrence of
renal failure in the absence of severe liver damage, and that
renal damage should always be kept in mind in patients who
have not received adequate treatment for paracetamol poison-
ing.
P. Pillans
C.Hall
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Modified chymopapain administration
The FDA Drug Bulletin for August 1984 notes that the re-
commended procedures for administering chymopapain for
disc lesions have been modified after reports of serious neuro-
logical events associated with the drug. Both the American
manufacturers of chymopapain have sent out letters to relevant
health professionals about the adverse effects and the new
recommendations.
Chymopapain was approved in 1982 by the FDA for intra-
discal injection to treat patients with herniated intervertebral
discs not responding to conservative therapy.
The number of serious neurological adverse events has not
been great in comparison with the number of patients involved.
It is estimated by one manufacturer that 72 000 patients have
been treated with chymopapain and only 30 have experienced
a serious adverse reaction, including paraplegia or paraparesis,
cerebral haemorrhage or transverse myelitis. Another manu-
facturer has reported 16 cases among 50000 patients world-
Beclomethasone and eczema
Atopic eczema in its more severe manifestations can be a
nightmarish condition to manage in children. Steroid drugs
such as prednisolone can be very effective when given syste-
mically, but have the disadvantages of serious side-effects and
difficulty in weaning patients off them, so that clinicians are
reluctant to use them. Since it had been noted that high-dose
beclomethasone dipropionate given by inhalation to children
with asthma had also improved their eczema, a trial was
designed in which children with atopic eczema were given
beclomethasone dipropionate orally and nasally (Heddle et al.,
Br Med] 1984; 289: 651-654). Beclomethasone is systemically
absorbed and rapidly metabolized in the liver to inactive
Dexamethasone as an anti-emetic
One of the major side-effects of cancer chemotherapy is the
nausea and vomiting which it may produce. Not infrequently,
cytotoxic 'cocktails' have to be discontinued or modified
because of this distressing effect, and can easily lead patients
to believe that the cure of the disease may well be worse than
simply putting up with it. The commonly used anti-emetics
have only been moderately successful, and more effective
drugs are constantly being sought. One of these appears to be
dexamethasone, which was compared with prochlorperazine in
42 patients undergoing chemotherapy for cancer (Markman et
wide. Patients receiving injections in two or more disc spaces
appear to be at increased risk.
It is now recommended that the procedure for administering
chymopapain be modified as follows: discography should be
carried out at least 3 - 4 days before the chymopapain injection
and not as part of the procedure. Secondly, an injection of
saline or water into the nucleus pulposus should precede
chymopapain injection and this should take place in conjunction
with high-quality X-ray views of the disc. If there is any
question about satisfactory placement of the needle, the pro-
cedure should be abandoned. The injection should also be
limited to one disc unless there are definite indications that
more than one disc is involved. Since most of the serious
neurological complications have occurred when general anaes-
thesia was used, local anaesthesia is recommended whenever
possible. Lastly, the manufacturers stress the need for special
training in chemonucleolysis before undertaking the procedure.
metabolites. Although it has been used extensively in the
prophylaxis of asthma, it has given rise to few local or systemic
adverse effects.
Twenty-seven children with moderate or severe atopic
eczema were treated in this trial, which was double-blind and
placebo-controlled with cross-over. All the criteria studied,
measured clinically and assessed parentally, improved on this
treatment, and no adverse side-effects were noted. The reason
for giving combined nasal and oral beclomethasone was that it
seemed more effective than either oral or nasal beclomethasone
alone.
al., N Engl ] Med 1984; 311: 549). The drug was well
tolerated; 25 patients taking dexamethasone experienced no
nausea compared with 14 taking prochlorperazine, and 29
patients did not vomit compared with 18 receiving prochlor-
perazine. Somnolence was noted in both groups, but was less
evident in those patients on dexamethasone (12%) than in
those on prochlorperazine (60%).
Dexamethasone appears to be a safe and effective anti-
emetic in these patients.
